TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7662616
Drug: Gelatin capsules
Normalized name: Gelatin Capsules
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin capsules coated with 20% w/v sodium alginate
Study: 7662616
Drug: Uncoated gelatin
Normalized name: Gelatin
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncoated gelatin capsules
Study: 2748113
Drug: Epinephrine treatment
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine treatment with Ocufen (flurbiprofen)
Study: 2748113
Drug: Epinephrine treatment
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine treatment with Indocid (indomethacin)
Study: 7006581
Drug: Epinephrine treatment
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine treatment alone
Study: 201786
Drug: Pivmecillinam 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivmecillinam 400 mg per day
Study: 201786
Drug: Amoxicillin 2000
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin 2000 mg per day
Study: 28273285
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus optional GPIs (control group)
Study: 21737486
Drug: FDTV 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDTV 180 mg + T 2 mg, once a day
Study: 21737486
Drug: T 2
Normalized name: EVT 201
DrugBank: EVT 201 (DB05721)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T 2 mg once a day
Study: 15254051
Drug: CEE +
Normalized name: Conjugated Estrogen Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE + MPA continuous (10 mg on days 1 to 12 per 28‐day cycle)
Study: 15254051
Drug: CEE +
Normalized name: Conjugated Estrogen Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE + MPA cyclical (10 mg on days 1 to 12 per 28‐day cycle)
Study: 15254051
Drug: CEE +
Normalized name: Conjugated Estrogen Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE + MP (200 mg on days 1 to 12 per 28‐day cycle)
Study: 29381666
Drug: CEE (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE (0.625 mg/d)
Study: 11177038
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray, 200 microg once daily
Study: 2570798
Drug: Terfenadine, 60
Normalized name: Terfenadine, 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine, 60 mg twice daily
Study: 2418304
Drug: HOE 498
Normalized name: CASTOR OIL 3 mg in 30 mg / ROSEMARY 4.5 mg in 30 mg / TOCOPHEROL 9 mg in 30 mg TOPICAL LIQUID [HOEGOA Herbal Hair Growth OiI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOE 498 (20 mg)
Study: 2992562
Drug: HOE 498
Normalized name: CASTOR OIL 3 mg in 30 mg / ROSEMARY 4.5 mg in 30 mg / TOCOPHEROL 9 mg in 30 mg TOPICAL LIQUID [HOEGOA Herbal Hair Growth OiI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOE 498 (50 mg)
Study: 2992562
Drug: HOE 498
Normalized name: CASTOR OIL 3 mg in 30 mg / ROSEMARY 4.5 mg in 30 mg / TOCOPHEROL 9 mg in 30 mg TOPICAL LIQUID [HOEGOA Herbal Hair Growth OiI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOE 498 (all doses)
Study: 25377592
Drug: FTMB (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTMB (0.5, 1.5, 3.0, or 6.0 mg/kg)
Study: 25377592
Drug: Herceptin(®) (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herceptin(®) (6 mg/kg)
Study: 20626050
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment protocol including bilateral use of acupoints (Fengchi (GB20), Taiyang (EX‐HN5), etc.), manual stimulation, 30 minutes per session, 20 needles per session, total duration of at least 10 weeks, treatment frequency of twice a week with one week rest between the first 10 and last 10 sessions.
Study: 10548704
Drug: Ketamine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (200 mg)
Study: 10548704
Drug: Fentanyl (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.2 mg)
Study: 14964737
Drug: Intramuscular lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular lidocaine
Study: 30448246
Drug: Intralesional 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional 5-fluorouracil (5-FU) injections
Study: 30566004
Drug: Liraglutide (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.8 mg or maximum tolerated dose)
Study: 26743240
Drug: Exenatide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (10 μg/day, n = 21)
Study: 26743240
Drug: Liraglutide (0.3-0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (0.3-0.9 mg/day, n = 19)
Study: 25108586
Drug: iv-B (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv-B (intravenous oxytocin when anterior shoulder seen)
Study: 25108586
Drug: iv-A (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv-A (intravenous oxytocin after delivery of the fetus)
Study: 25108586
Drug: im-A (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: im-A (intramuscular oxytocin after delivery)
Study: 25108586
Drug: im-B (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: im-B (intramuscular oxytocin when anterior shoulder seen)
Study: 21833852
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ultrasonography and physical examination
Study: 17324825
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of epinastine hydrochloride
Study: 17324825
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of chlorpheniramine maleate
Study: 7890211
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Isosorbide-5-mononitrate (Is-5-Mn)
Study: 7890211
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Isosorbide-5-mononitrate (Is-5-Mn)
Study: 2197583
Drug: Preoperative controlled
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative controlled infusion of 10 mg Propionibacterium avidum KP‐40
Study: 656269
Drug: Bumetanide (0.5-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide (0.5-2 mg)
Study: 656269
Drug: Frusemide (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide (dose not specified)
Study: 656269
Drug: Bumetanide and
Normalized name: bumetanide and potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide and Frusemide (high dosage in renal failure)
Study: 25671798
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus endovascular treatment with thrombectomy devices
Study: 22308561
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (waiting-list control)
Study: 19178404
Drug: Amoxicillin hapten
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin hapten
Study: 11079280
Drug: Oral ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ondansetron 16 mg plus dexamethasone 12 mg
Study: 11079280
Drug: Oral granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral granisetron 1 mg plus dexamethasone 12 mg
Study: 8363029
Drug: Intravenous analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous analgesia with tramadol/metamizol (max. tramadol 400 mg+metamizol 5 g in any 24 h) after major surgery and additional administration of piritramide as needed (max. 60 mg/24 h.i.v.)
Study: 8363029
Drug: Ibuprofen (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (3 x 500 mg) after minor surgery
Study: 3012072
Drug: Smoking a
Normalized name: Publix Stop Smoking Aid 4mg Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking a single 1-g marihuana cigarette containing 1.8% delta 9-tetrahydrocannabinol
Study: 31366458
Drug: Positive airway
Normalized name: VersaPAP Positive Airway Pressure Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive airway pressure treatment
Study: 17042168
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene instruction (OHI) alone
Study: 17042168
Drug: OHI and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OHI and metronidazole dental gel
Study: 17042168
Drug: OHI and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OHI and subgingival scaling plus metronidazole gel
Study: 8801192
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid supplementation (500 mg twice daily for two weeks)
Study: 1377455
Drug: Nalbuphine 1
Normalized name: nalbuphine 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 1 mg/kg i.v.
Study: 30532779
Drug: Low-Level Laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Level Laser Therapy (LLLT)
Study: 30235384
Drug: Topical Epidermal
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Epidermal Growth Factor (EGF) serum applied twice daily for eight weeks
Study: 30235384
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied twice daily for eight weeks
Study: 30235384
Drug: Topical Epidermal
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Epidermal Growth Factor (EGF) serum
Study: 17230307
Drug: Subcutaneous anterior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous anterior transposition of the nerve
Study: 12198065
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg IM phenylephrine
Study: 12198065
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg IM phenylephrine
Study: 9989959
Drug: Automated heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated heparin control system (AutoHep) with initial bolus of heparin
Study: 9989959
Drug: Automated heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated heparin control system (AutoHep) without initial bolus of heparin
Study: 1730312
Drug: Conventional infertility
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional infertility treatment (induction of ovulation with gonadotropins followed by intrauterine artificial insemination or normal intercourse)
Study: 3548009
Drug: Butorphanol 2
Normalized name: butorphanol 2 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 2 mg
Study: 31008635
Drug: Preventive cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive cognitive therapy (PCT), 8 weekly sessions
Study: 29421065
Drug: 8% topical
Normalized name: BPO 8% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% topical capsaicin
Study: 15656211
Drug: GnRH analogue
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH analogue (leuprolide acetate, 3.75 mg, intramuscular injections every 28 days for 3 months)
Study: 15656211
Drug: Danazol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (400 mg orally, 2 times per day for 3 months)
Study: 15656211
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no postoperative treatment, underwent ovarian stimulation immediately after first menses within 3 months postoperatively)
Study: 9192396
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss in the first four weeks and daily food records completion
Study: 23146280
Drug: Adjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatment with paclitaxel (E-T-CMF)
Study: 23146280
Drug: Adjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatment with epirubicin followed by CMF (E-CMF)
Study: 20703222
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg intravenous dose of rifampin
Study: 20703222
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg dose of warfarin alone
Study: 10406365
Drug: Better pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Better pain treatment
Study: 2135070
Drug: Pyritinol 600
Normalized name: pyritinol
DrugBank: Pyritinol (DB13084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyritinol 600 mg
Study: 2135070
Drug: Pyritinol 1200
Normalized name: pyritinol
DrugBank: Pyritinol (DB13084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyritinol 1200 mg
Study: 378623
Drug: Oral L-dopa
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral L-dopa 1000 mg
Study: 378623
Drug: L-dopa placebo
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa placebo
Study: 22264208
Drug: 1% Alendronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Alendronate (ALN) gel
Study: 27091596
Drug: 1.2% Atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2% Atorvastatin (ATV) gel
Study: 31318225
Drug: Individualized assessment
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized assessment and treatment program (IATP)
Study: 17387131
Drug: Atorvastatin combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin combined with 60 mg of torcetrapib for 2 years
Study: 15492573
Drug: 40 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL/kg intraoperative administration of lactated Ringer's solution (LR)
Study: 15492573
Drug: 15 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL/kg intraoperative administration of lactated Ringer's solution (LR)
Study: 11446476
Drug: Enoxaparin 2,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 2,500 IU once daily
Study: 11446476
Drug: Standard Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Heparin 5,000 IU three times daily
Study: 9572995
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) 400 microg/m2 IV over 30 minutes once daily
Study: 8071389
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg twice daily for 4 days)
Study: 8071389
Drug: Temazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam (10 mg single oral dose)
Study: 3342282
Drug: Liquid formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid formulation of benzydamine hydrochloride with ICEBERG AR 84/05/15 flavoring agent
Study: 3342282
Drug: Liquid formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid formulation of benzydamine hydrochloride without ICEBERG AR 84/05/15 flavoring agent
Study: 31882376
Drug: Alirocumab (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (75 mg every 2 weeks, with dose increase to 150 mg every 2 weeks at week 12 if week 8 LDL-C was >1.81 mmol/L)
Study: 29266308
Drug: PF-06700841 30
Normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06700841 30 mg once daily
Study: 29266308
Drug: PF-06700841 100
Normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06700841 100 mg once daily
Study: 29266308
Drug: PF-06700841 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06700841 (various doses)
Study: 25119580
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with warning about side effects
Study: 25119580
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment without warning about side effects
Study: 25119580
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment with warning about side effects
Study: 25119580
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment without warning about side effects
Study: 23672267
Drug: rhANP 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhANP 0.1 μg/kg/min
Study: 23672267
Drug: rhANP 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhANP 0.2 μg/kg/min
Study: 23672267
Drug: rhANP 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhANP 0.05 μg/kg/min
Study: 20439384
Drug: School-based nurse-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based nurse-directed smokeless tobacco cessation intervention including peer-led educational sessions and oral exams by the school nurse with brief tobacco cessation counseling.
Study: 18520292
Drug: Bevacizumab at
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab at 15 mg/kg every 3 weeks
Study: 18520292
Drug: Bevacizumab at
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab at 7.5 or 15 mg/kg every 3 weeks
Study: 12687554
Drug: Alendronate (ALN)
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate (ALN) discontinued (<90 days of therapy)
Study: 10227337
Drug: Salmeterol (42
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (42 microg twice daily)
Study: 10400478
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) (84 microg four times daily)
Study: 8911782
Drug: Purified micronized
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified micronized flavonoid fraction (Daflon 500 mg)
Study: 1868678
Drug: ciprofloxacin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: ciprofloxacin (750 mg every 12 hours for five doses)
Study: 1868678
Drug: temafloxacin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: temafloxacin (600 mg every 12 hours for five doses)
Study: 1868678
Drug: placebo (given
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (given every 12 hours for five doses)
Study: 31977858
Drug: Vicagrel 5
Normalized name: Vicagrel
DrugBank: Vicagrel (DB16349)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicagrel 5 mg
Study: 30326264
Drug: Vicagrel 20
Normalized name: Vicagrel
DrugBank: Vicagrel (DB16349)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicagrel 20 mg
Study: 30326264
Drug: Vicagrel 25
Normalized name: Vicagrel
DrugBank: Vicagrel (DB16349)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicagrel 25 mg
Study: 15612841
Drug: Naturally occurring
Normalized name: Naturally occurring alkaloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naturally occurring (NO) marriage preparation
Study: 11352439
Drug: Calcium 500mg
Normalized name: CALCIUM 500MG TAB
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 500mg (Calcium‐Sandoz Forte) administered before, and 12 and 24 hours after moxifloxacin
Study: 9164427
Drug: buspirone 30
Normalized name: busPIRone 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: buspirone 30 mg daily
Study: 8220803
Drug: Budesonide 400
Normalized name: Budesonide 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 400 micrograms once daily
Study: 8220803
Drug: Budesonide 200
Normalized name: budesonide 200 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 200 micrograms once daily
Study: 26285691
Drug: Nebivolol 10
Normalized name: nebivolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 10 mg daily
Study: 26285691
Drug: Metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol succinate 100 mg daily
Study: 20555272
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment groups (DD and RB)
Study: 9625841
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy in NSCLC (14 patients)
Study: 9625841
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy in SCLC (9 patients)
Study: 3286783
Drug: Norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (400 mg) every 12 hours for 28 days
Study: 22940254
Drug: Herbal medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Herbal medicines only (57 patients)
Study: 22940254
Drug: Herbal and
Normalized name: ALLANTOIN 1 g in 100 g TOPICAL CREAM [Scar Reducer Intensive Herbal and Nutrient]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal and conventional medicines concurrently (256 patients)
Study: 20729255
Drug: Synbiotic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic preparation (Lactobacillus helveticus R0052, Bifidobacterium infantis R0033, Bifidobacterium bifidum R0071, and fructooligosaccharide)
Study: 2852948
Drug: Chemotherapy (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (cisplatin and etoposide)
Study: 31880479
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of treatment with 36 or 54 mg extended release methylphenidate for 7 weeks
Study: 28627070
Drug: Hydrolysed wheat
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrolysed wheat flour (10 g of gluten/d for 3 days)
Study: 28627070
Drug: Natural wheat
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural wheat flour (10 g of gluten/d for 3 days)
Study: 26545731
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Entonox and play therapy
Study: 17435692
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg intravitreal triamcinolone acetonide injection
Study: 14518703
Drug: Twice-a-day low-pill
Normalized name: Aspir-Low Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-a-day low-pill burden regimen (EFV+Combivir)